Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Business Wire•18/11/2026•09:10 ET
0
Key Highlights
- ➤ADEPT-1 NPI-C H+D score fell 12.0 points over 12 weeks
- ➤ADEPT-3 enrolled 401 participants; 273 completed 52 weeks
- ➤ADEPT-3 reported 4.7% discontinuation rate through Week 52
- ➤ADEPT-1 reported 4.4% discontinuation rate during open-label treatment
- ➤KarXT produced no new safety signals across both studies
Expert Statements
Jeffrey L. Cummings, Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience in the Kirk Kerkorian School of Medicine at UNLV
“These preliminary findings further our understanding of the possible impact of KarXT in this setting as we work to uncover new ways to help alleviate the added burden of psychosis for patients and families living with this devastating condition.”
Cristian Massacesi, Executive vice president, chief medical officer and head of development, Bristol Myers Squibb
“We believe the improvement in hallucinations and delusion scores in ADEPT-1 and the long-term safety and tolerability findings shown in ADEPT-3 are encouraging as we await results from the double-blind periods of the ADEPT program.”
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baseline
Get started
Create a free account to read the full story.
